Zobrazeno 1 - 10
of 172
pro vyhledávání: '"Seong Eon Ryu"'
Publikováno v:
STAR Protocols, Vol 5, Iss 2, Pp 102999- (2024)
Summary: The microbial transcription factor YhaJ responds to 2,4-dinitrotoluene (DNT) derivatives. Here, we describe steps for overexpression and purification of the protein, characterization for the binding of a DNT derivative methylhydroquinone, an
Externí odkaz:
https://doaj.org/article/d8de99ada43c4317aa624c8250201958
Publikováno v:
iScience, Vol 26, Iss 10, Pp 107984- (2023)
Summary: Detection of landmines without harming personnel is a global issue. The bacterial transcription factor YhaJ selectively detects metabolites of explosives, and it can be used as a key component of DNT biosensors. However, the wild-type YhaJ h
Externí odkaz:
https://doaj.org/article/8629e1db67c743a4a7938cbe2eff6540
Autor:
Jain Ha, Sewoong Lee, Jiyoung Park, Jihye Seo, Eunjeong Kang, Haelim Yoon, Ba Reum Kim, Hyeon Kyu Lee, Seong Eon Ryu, Sayeon Cho
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract When primary cancer faces limited oxygen and nutrient supply, it undergoes an epithelial–mesenchymal transition, which increases cancer cell motility and invasiveness. The migratory and invasive cancer cells often exert aggressive cancer d
Externí odkaz:
https://doaj.org/article/0159a810a6fa4038bcbcf137a069a74a
Autor:
Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee, Ji Young Son, Jee Un Lee, Ki-Young Yoo, Seong Eon Ryu, Jaejun Rhie, Ju Yeon Lee, Yong-Seok Heo
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Blocking B-cell activating factor (BAFF), an important soluble factor for B-cell responses, with specific antibodies is approved for treating autoimmune disorders. Here the authors show, with structural data, that antibody-BAFF interactions not only
Externí odkaz:
https://doaj.org/article/e330576c14f6477d992a74d39ff8392f
Autor:
Hyun Tae Lee, Ju Yeon Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin, Yong-Seok Heo
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trial
Externí odkaz:
https://doaj.org/article/b9c8ef6cf5af47aca2205e92c9d3f1e9
Autor:
Minjin Yoo, Tae Hyun Park, Miyoun Yoo, Yeongrin Kim, Joo-Youn Lee, Kyu Myung Lee, Seong Eon Ryu, Byung Il Lee, Kwan-Young Jung, Chi Hoon Park
Publikováno v:
Molecules, Vol 26, Iss 6, p 1686 (2021)
Epigenetic regulation is known to play a key role in progression of anti-cancer therapeutics. Lysine acetylation is an important mechanism in controlling gene expression. There has been increasing interest in bromodomain owing to its ability to modul
Externí odkaz:
https://doaj.org/article/7126f47094d24e8fad469e64c65ac9b2
Autor:
Ju Yeon Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee, Seong Eon Ryu, Ji Young Son, Jee Un Lee, Yong-Seok Heo
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Immunotherapy is offering patients with cancer new therapy options. Here, the authors report on the crystal structures of some of these therapies bound to their targets.
Externí odkaz:
https://doaj.org/article/405043e189914752b01da6da98777da8
Autor:
Bonsu Ku, Won Hong, Chae Won Keum, Myeongbin Kim, Hyunyeol Ryu, Donghwan Jeon, Ho-Chul Shin, Jae Hoon Kim, Seung Jun Kim, Seong Eon Ryu
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187701 (2017)
Dual-specificity phosphatases (DUSPs) constitute a subfamily of protein tyrosine phosphatases, and are intimately involved in the regulation of diverse parameters of cellular signaling and essential biological processes. DUSP28 is one of the DUSP sub
Externí odkaz:
https://doaj.org/article/0064f92b00784bdcb7bf6c05ac3fc40c
Autor:
Suk Hyun Yoo, Seong Eon Ryu
Publikováno v:
Korean Society for Structural Biology. 11:1-10
Publikováno v:
BIODESIGN. 10:17-22